$RLFTF (related) copy by frenchman yhoobrd - Many of us

New Post Public Reply Private Reply Replies (1) Message Board
mc67
375
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:

“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.

Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?

As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.

Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.

The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.

The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.

Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”

https://thedispatch.com/p/fda-career-staff-are-delaying-the

- some replies -

Zaran
thank you, sorry state we are in


m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.


Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.

Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?


m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.


Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.

What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.


crymeariver
They should focus on saving dying people instead of vaccinating healthy people.


frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 3

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 5

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 1

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 6

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 4

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading

Top 5 Most Recently Viewed Articles

Aviation MRO Software Market Sees Growth Driven by Innovation

Updated Category News Views 106

Aviation MRO Software Market Sees Promising Growth According to recent insights, the aviation MRO software market is set for substantial growth, with a projected valuation of USD 9.56 billion by 2030. This represents a steady increase from a value of USD 7.72 billion in earlier years. The growth is attributed to the shift towards cloud-based MRO platforms, which enhance...

Continue Reading
Power Nickel Unveils Impressive Results from Recent Drilling

Updated Category News Views 117

Power Nickel's Outstanding Drilling Results Power Nickel Inc (NASDAQ: PNPNF) has announced significant results from its recent drilling campaign, particularly focusing on Hole PN-24-078. This hole has returned an average of over 29.5 meters wide polymetallic zone, showcasing remarkable grades, with copper equivalent (CuEq) values ranging from 2.3% to 11%. Highlights from...

Continue Reading
Engaging Chat with Bull Rider Derek Kolbaba on UNLEASHED

Updated Category News Views 727

Monster Energy's UNLEASHED Podcast Features Bull Rider Derek Kolbaba In a special live episode, Monster Energy proudly presents Derek Kolbaba, one of the toughest bull riders on the PBR circuit. Episode 504 of the popular sports and pop culture podcast UNLEASHED with hosts Brittney Palmer, Danny, and the late Luke 'Dingo' Trembath dives deep into Kolbaba's journey in the...

Continue Reading
Impressive Progress on the New Palace Museum Branch's Structure

Updated Category News Views 230

Striking Advances in the Palace Museum's New Branch The construction of a new branch of the Palace Museum is making noteworthy strides. The main structure of this facility, located in the Haidian district, is on track to reach its primary structural milestone in the near future. This ambitious project is poised to mark a significant chapter in the museum's centennial...

Continue Reading
Johnston Tobey Baruch Shareholders Recognized as Top Attorneys

Updated Category News Views 111

Recognition of Excellence in Law Johnston Tobey Baruch proudly announces that its shareholders, Robert Tobey and Chad Baruch, have been recognized in Lawdragon’s esteemed list of 500 Leading Lawyers in America for the year 2025. This celebrated legal guide holds a reputation for spotlighting the finest attorneys across the nation, making this acknowledgment significant....

Continue Reading